HLB PANAGENE Co., LTD. (KOSDAQ:046210)

Market Cap	89.60B
Revenue (ttm)	13.33B
Net Income (ttm)	-3.10B
Shares Out	45.03M
EPS (ttm)	-74.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	105,561
Average Volume	81,776
Open	2,035.00
Previous Close	2,000.00
Day's Range	1,995.00 - 2,135.00
52-Week Range	1,665.00 - 5,340.00
Beta	0.48
RSI	31.84
Earnings Date	Aug 14, 2025

About HLB PANAGENE Co., LTD.

HLB PANAGENE Co., LTD. develops products in the field of molecular diagnostics in South Korea. Its products include liquid biopsy products for lung and colon cancers; tissue biopsy products for lung, thyroid, pancreatic, and colon cancers, as well as glioblastoma, myeloproliferative neoplasm, chronic myelogenous leukemia, central nervous system, myelofibrosis, and polycythemia vera diseases. The company also offers products for cervical cancer, sexually transmitted, and extreme drug resistance diseases; and peptide nucleic acid products. The co...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1976
• Employees: 81
• Stock Exchange: KOSDAQ
• Ticker Symbol: 046210

Financial Performance

In 2024, HLB PANAGENE Co., LTD.'s revenue was 13.20 billion, an increase of 7.71% compared to the previous year's 12.25 billion. Losses were -1.94 billion, -59.63% less than in 2023.